Potential Effects Immunomodulators on Probiotics in COVID-19 Preventing Infection in the Future. A Narrative Review

  • Muhammad Luthfi Adnan Universitas Islam Indonesia
  • Miranti D. Dewi Islamic University of Indonesia
Keywords: COVID-19 virus infection, Inflammation, Probiotics, Immune system, Review Literature as Topic

Abstract

After the outbreak in December 2019, Coronavirus Disease (COVID-19) has become a global health problem because of its rapid spread throughout the world. To date, there are no effective therapies to treat or prevent COVID-19 infection. Probiotic bacteria are widely used to prevent gastrointestinal infections by modulating intestinal microbiota. Therefore, this literature review focuses on the potential possessed by probiotic bacteria for the prevention of future COVID-19 infections. Information was extracted from PubMed and Google Scholar using the keywords: "COVID-19", "immunomodulator", "inflammation", and "probiotic" and synthesize in a narrative review. The results showed that probiotic bacteria have immunomodulatory activity that can increase immunity against pathogens by regulating the immune system through modulation of intestinal microbiota and interactions with the lymphatic system in the digestive tract. The ability of the immune system regulation by probiotic bacteria has the effect of increasing the body's defense mechanisms against pathogens that infect the respiratory tract. However, further evidence is still needed regarding the effect of probiotic immunomodulators in combating future COVID-19 infections.

Author Biographies

Muhammad Luthfi Adnan, Universitas Islam Indonesia

Medical student

Miranti D. Dewi, Islamic University of Indonesia

Master of Science, Department of Physiology

References

Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J. & Hsueh, P. R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents 55, 105924 (2020).

Guo, Y.-R. et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil. Med. Res. 7, 1–10 (2020).

Sun, P., Lu, X., Xu, C., Sun, W. & Pan, B. Understanding of COVID-19 based on current evidence. J. Med. Virol. 0–1 (2020). doi:10.1002/jmv.25722

Malemud, C. J. Immunomodulators in Autoimmunity and Viral Infections. J. Clin. Cell. Immunol. 09, (2018).

Kanauchi, O., Andoh, A., AbuBakar, S. & Yamamoto, N. Probiotics and Paraprobiotics in Viral Infection: Clinical Application and Effects on the Innate and Acquired Immune Systems. Curr. Pharm. Des. 24, 710–717 (2018).

Prompetchara, E., Ketloy, C. & Palaga, T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific J. allergy Immunol. (2020). doi:10.12932/AP-200220-0772

Qin, C. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China Chuan. Clin. Infect. Dis. (2020). doi:10.1017/CBO9781107415324.004

Mahallawi, W. H., Khabour, O. F., Zhang, Q., Makhdoum, H. M. & Suliman, B. A. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine 104, 8–13 (2018).

Raoult, D., Zumla, A., Locatelli, F., Ippolito, G. & Kroemer, G. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress 4, 66–75 (2020).

Lehtoranta, L., Pitkäranta, A. & Korpela, R. Probiotics in respiratory virus infections. Eur. J. Clin. Microbiol. Infect. Dis. 33, 1289–1302 (2014).

Mohanty, D. & Ray, P. Evaluation of probiotic and antimicrobial properties of lactobacillus strains isolated from dairy products. Int. J. Pharm. Pharm. Sci. 8, 230–234 (2016).

Monteagudo-Mera, A., Rastall, R. A., Gibson, G. R., Charalampopoulos, D. & Chatzifragkou, A. Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health. Appl. Microbiol. Biotechnol. 103, 6463–6472 (2019).

Garcia-Gonzalez, N., Prete, R., Battista, N. & Corsetti, A. Adhesion properties of food-associated lactobacillus plantarum strains on human intestinal. Front. Microbiol. 9, 1–11 (2018).

Hemarajata, P. & Versalovic, J. Effects of probiotics on gut microbiota: Mechanisms of intestinal immunomodulation and neuromodulation. Therap. Adv. Gastroenterol. 6, 39–51 (2013).

Zhang, C. xing, Wang, H. yu & Chen, T. xin. Interactions between Intestinal Microflora/Probiotics and the Immune System. Biomed Res. Int. 2019, (2019).

McFarland, L. V. Systematic review and meta-analysis of saccharomyces boulardii in adult patients. World J. Gastroenterol. 16, 2202–2222 (2010).

Arora, T., Singh, S. & Sharma, R. K. Probiotics: Interaction with gut microbiome and antiobesity potential. Nutrition 29, 591–596 (2013).

Bellikci-Koyu, E. et al. Effects of regular kefir consumption on gut microbiota in patients with metabolic syndrome: A parallel-group, randomized, controlled study. Nutrients 11, 1–23 (2019).

Lazarenko, L. M. et al. IMUNOBIOTICS ARE THE NOVEL BIOTECH DRUGS WITH ANTIBACTERIAL AND IMMUNOMODULATORY PROPERTIES. ікробіологічний журнал 7, 66–75 (2017).

Villena, J. et al. Immunobiotic Lactobacillus rhamnosus strains differentially modulate antiviral immune response in porcine intestinal epithelial and antigen presenting cells. BMC Microbiol. 14, 1–14 (2014).

Tada, A. et al. Immunobiotic Lactobacillus strains reduce small intestinal injury induced by intraepithelial lymphocytes after Toll-like receptor 3 activation. Inflamm. Res. 65, 771–783 (2016).

Zhang, H. et al. Prospective study of probiotic supplementation results in immune stimulation and improvement of upper respiratory infection rate. Synth. Syst. Biotechnol. 3, 113–120 (2018).

Dickson, R. P., Erb-Downward, J. R. & Huffnagle, G. B. The role of the bacterial microbiome in lung disease. Expert Rev. Respir. Med. 7, 245–257 (2013).

Rosa, D. D. et al. Milk kefir: Nutritional, microbiological and health benefits. Nutr. Res. Rev. 30, 82–96 (2017).

Oeser, K., Maxeiner, J., Symowski, C., Stassen, M. & Voehringer, D. T cells are the critical source of IL-4/IL-13 in a mouse model of allergic asthma. Allergy Eur. J. Allergy Clin. Immunol. 70, 1440–1449 (2015).

Li, B., Zheng, J., Zhang, X. & Hong, S. Probiotic Lactobacillus casei Shirota improves efficacy of amoxicillin-sulbactam against childhood fast breathing pneumonia in a randomized placebo-controlled double blind clinical study. J. Clin. Biochem. Nutr. 63, 233–237 (2018).

Natarajan, N. & Pluznick, J. L. From microbe to man: The role of microbial short chain fatty acid metabolites in host cell biology. Am. J. Physiol. - Cell Physiol. 307, C979–C985 (2014).

Shukla, S. D., Budden, K. F., Neal, R. & Hansbro, P. M. Microbiome effects on immunity, health and disease in the lung. Clin. Transl. Immunol. 6, e133-12 (2017).

He, Y. et al. Gut–lung axis: The microbial contributions and clinical implications. Crit. Rev. Microbiol. 43, 81–95 (2017).

Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).

Tisoncik, J. R. et al. Into the Eye of the Cytokine Storm. Microbiol. Mol. Biol. Rev. 76, 16–32 (2012).

Raphael, I., Nalawade, S., Eagar, T. N. & Forsthuber, T. G. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 74, 5–17 (2015).

Qian, L. J. et al. Early-life gut microbial colonization shapes Th1/Th2 balance in asthma model in BALB/c mice. BMC Microbiol. 17, 1–8 (2017).

Grayson, M. H. et al. Intestinal microbiota disruption reduces regulatory T cells and increases respiratory viral infection mortality through increased IFNγ production. Front. Immunol. 9, 7–9 (2018).

Mortaz, E. et al. Probiotics in the management of lung diseases. Mediators Inflamm. 2013, (2013).

Vareille-Delarbre, M. et al. Immunomodulatory effects of lactobacillus plantarum on inflammatory response induced by klebsiella pneumoniae. Infect. Immun. 87, (2019).

Wu, C. T., Chen, P. J., Lee, Y. T., Ko, J. L. & Lue, K. H. Effects of immunomodulatory supplementation with Lactobacillus rhamnosus on airway inflammation in a mouse asthma model. J. Microbiol. Immunol. Infect. 49, 625–635 (2016).

Kuo, C. et al. Rhinovirus infection induces expression of airway remodelling factors in vitro and in vivo. Respirology 16, 367–377 (2011).

Azad, M. A. K., Sarker, M. & Wan, D. Immunomodulatory Effects of Probiotics on Cytokine Profiles. Biomed Res. Int. 2018, (2018).

Published
2020-05-08
How to Cite
Adnan, M. L., & Dewi, M. D. (2020). Potential Effects Immunomodulators on Probiotics in COVID-19 Preventing Infection in the Future. A Narrative Review. International Journal of Medical Students. https://doi.org/10.5195/ijms.2020.486
Section
Review